



Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study

Savino Sciascia^{1,2*†}, Massimo Radin^{1,3†}, Irene Cecchi^{1,3}, Elena Rubini^{1,3}, Anna Scotta^{1,3,4}, Roberta Rolla⁴, Barbara Montaruli⁵, Patrizia Pergolini⁴, Giulio Mengozzi⁶, Emanuela Muccini⁶, Simone Baldovino^{1,3}, Michela Ferro², Antonella Vaccarino⁷, Michael Mahler⁸, Elisa Menegatti³ and Dario Roccatello^{1,2}

OPEN ACCESS

Edited by:

Ricard Cervera,
Hospital Clínic de Barcelona, Spain

Reviewed by:

Jason S. Knight,
University of Michigan, United States
Ian P. Giles,
University College London,
United Kingdom

*Correspondence:

Savino Sciascia
savino.sciascia@unito.it

[†]These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Autoimmune and Autoinflammatory
Disorders,
a section of the journal
Frontiers in Immunology

Received: 30 November 2018

Accepted: 14 February 2019

Published: 05 March 2019

Citation:

Sciascia S, Radin M, Cecchi I,
Rubini E, Scotta A, Rolla R,
Montaruli B, Pergolini P, Mengozzi G,
Muccini E, Baldovino S, Ferro M,
Vaccarino A, Mahler M, Menegatti E
and Roccatello D (2019) Reliability of
Lupus Anticoagulant and
Anti-phosphatidylserine/prothrombin
Autoantibodies in Antiphospholipid
Syndrome: A Multicenter Study.
Front. Immunol. 10:376.
doi: 10.3389/fimmu.2019.00376

¹ Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy, ² Nephrology and Dialysis Unit, S. Giovanni Bosco Hospital and University of Turin, Turin, Italy, ³ Department of Clinical and Biological Sciences, School of Specialization of Clinical Pathology, University of Turin, Turin, Italy, ⁴ AOU Clinical Chemistry Laboratory, "Maggiore della Carità" University Hospital, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy, ⁵ AO Ordine Mauriziano, Turin, Italy, ⁶ Department of Clinical Biochemistry, AOU Città della Salute e della Scienza, Turin, Italy, ⁷ Hematology Division, and S. Giovanni Bosco Hospital, Turin, Italy, ⁸ Inova Diagnostics, Research and Development, San Diego, CA, United States

Background: Is it well-known that one of the major drawbacks of Lupus Anticoagulant (LA) test is their sensitivity to anticoagulant therapy, due to the coagulation based principle. In this study we aimed to assess the reproducibility of LA testing and to evaluate the performance of solid assay phosphatidylserine/prothrombin (aPS/PT) antibodies.

Methods: We included 60 patients that fulfilled the following inclusion criteria: (I) diagnosis of thrombotic antiphospholipid syndrome (APS); (II) patients with thrombosis and (a) inconstant previous LA positivity and/or (b) positivity for antiphospholipid antibodies (aPL) at low-medium titers [defined as levels of anti- β 2Glycoprotein-I or anticardiolipin (IgG/IgM) 10–30 GPL/MPL] with no previous evidence of LA positivity. aPL testing was performed blindly in 4 centers undertaking periodic external quality assessment.

Results: The 60 patients enrolled were distributed as follows: 43 (71.7%) with thrombotic APS, 7 (11.7%) with thrombosis and inconstant LA positivity and 10 (16.7%) with low-medium aPL titers. Categorical agreement for LA among the centers ranged from 0.41 to 0.60 (*Cohen's kappa* coefficient; moderate agreement). The correlation determined at the 4 sites for aPS/PT was strong, both quantitatively (Spearman rho 0.84) and when dichotomized (*Cohen's kappa* coefficients = 0.81 to 1.0). Discordant (as defined by lack of agreement in ≥ 3 laboratories) or inconclusive LA results were observed in 27/60 (45%) cases; when limiting the analysis to those receiving vitamin K antagonist (VKA), the level of discordant LA results was as high as 75%(15/20). Conversely, aPS/PT testing showed an overall agreement of 83% (up to 90% in patients receiving VKA), providing an overall increase in test reproducibility of +28% when compared to LA,

becoming even more evident (+65%) when analyzing patients on VKA. In patients treated with VKA, we observed a good correlation for aPS/PT IgG testing (*Cohen's kappa* coefficients = 0.81–1; Spearman rho 0.86).

Conclusion: Despite the progress in the standardization of aPL testing, we observed up to 45% of overall discrepant results for LA, even higher in patients on VKA. The introduction of aPS/PT testing might represent a further diagnostic tool, especially when LA testing is not available or the results are uncertain.

Keywords: antiphospholipid syndrome, Antiphospholipid Antibodies, Lupus Anticoagulant, aPS/PT, thrombosis, laboratory, diagnostic performance, reliability

INTRODUCTION

Since clinical features of Antiphospholipid Syndrome (APS) (thrombosis and pregnancy complications) are common in the general population and often related to other underlying factors, the diagnosis of APS requires next to clinical assessment the detection of persistently positive Antiphospholipid Antibodies (aPL). Thus, reliable laboratory tests with good clinical and analytical performance reproducibility are required. There is a large variety of assays available to assess aPL, but despite progress, standardization is still not optimal (1–3).

Lupus anticoagulant (LA) has been shown to be the strongest risk factor for aPL-related clinical manifestations (4), and the correct interpretation of this functional assay is crucial for diagnosis of APS. However, testing patients during treatment with vitamin K antagonists (VKA) or other oral anticoagulants remains a contentious issue and has been discouraged by official guidelines (5–7) because of interpretational problems affecting the mixing test. Besides, the clinical significance of low aPL titer and/or weak LA positivity, especially when detected in patients receiving anticoagulation [either VKA or direct anticoagulant agents (DOAC)], remains uncertain and certainly needs a more thorough evaluation.

More recently, the family of aPL has been expanded to include a heterogeneous group of autoantibodies whose specificity is directed to proteins involved in coagulation or to a complex of these proteins with phospholipids (8). Among others, autoantibodies that recognize a phosphatidylserine/prothrombin (aPS/PT) complex have been reported to be associated with APS and may have diagnostic relevance in these settings (9, 10). However, since aPS/PT antibodies are not currently included in the current APS classification criteria (11), aPS/PT antibodies are not assessed in all patients suspected to suffer from APS. Given the importance of aPL confirmation to improve the interpretability of laboratory test results for clinical trials and research studies, the objective of this study was to assess the reproducibility of LA and aPS/PT antibody testing when performed in different expert centers and to assess the diagnostic performance of these tests in different clinical settings of APS.

METHODS

Patients

We chart-reviewed patients with thrombotic events who tested persistently positive for at least one aPL (more than two occasions

over a time of more than 12 weeks) that presented at San Giovanni Bosco Hospital in the last 5 years. The study was performed in compliance with the Declaration of Helsinki; approval from the ethic committee was not required according to the local and national guidelines. We enrolled 60 patients who met one of the following inclusion criteria:

- 1) Fulfilled the diagnosis of thrombotic APS defined as per Sydney criteria (11).
- 2) Patients with thrombosis and suspected APS not completely fulfilling the laboratory criteria (11), as follows: (a) inconsistent previous LA positivity; and/or (b) low-medium aPL titers [defined as levels of anticardiolipin (aCL) IgG/IgM or anti- β 2-glycoprotein I (a β 2GPI) IgG/IgM antibodies 10–30 GPL/MPL]. Clinical and laboratory characteristics were retrospectively collected.

Previous Autoantibody Detection

The aPL profile, at the diagnosis, included aCL, LA, and a β 2GPI antibodies.

The aCL and a β 2GPI (IgG and IgM) were detected by commercial ELISA (Inova Diagnostics, Inc., San Diego, CA, US). Plasma samples were tested for the presence of LA according to the recommended criteria from the International Society on Thrombosis and Haemostasis (ISTH) Subcommittee on Lupus Anticoagulant/Phospholipid-Dependent Antibodies (12, 13).

Study Design

LA and aPS/PT testing was performed in a blind fashion in four centers of the “Antiphospholipid Antibodies Regional Consortium” in northwest Italy: San Giovanni Bosco Hospital, Turin, Italy, A.O.U. Città della Salute e della Scienza, Turin, Italy, A.O. Ordine Mauriziano, Turin, Italy, and A.O.U. Maggiore della Carità, Novara, Italy (14).

LA was tested with the detection of two different reagents, used as screening and confirmatory tests, Silica Clotting Time HemosIL and dRVVT Screen and Confirm HemosIL, respectively (Instrumentation Laboratory, Bedford, MA, USA). Both tests were automated on ACL TOP 750 LAS instruments and results were normalized by means of plasma pools obtained from healthy donors without any deficit in coagulation factors, as per the current criteria from the ISTH Subcommittee on LA-Phospholipid-dependent antibodies (12, 13).

Both IgG and IgM aPS/PT were assayed using commercial ELISA kits (QUANTA Lite[®], Inova Diagnostic), in accordance

with manufacturer's instructions. Samples were considered positive for aPS/PT IgG/IgM if tested >30 U.

Agreement was defined when all four laboratories had a concordant binomial result (positive/negative), both for LA and aPS/PT IgG/IgM testing.

Statistical Analysis

Categorical variables are presented as number (%) and continuous variables are presented as mean (S.D.). Categorical agreement and degree of linear association was analyzed. The significance of baseline differences was determined by the chi-squared test, Fisher's exact test or the unpaired *t*-test, as appropriate. A two-sided *p*-value < 0.05 was statistically significant. All statistical analyses were performed using SPSS version 19.0 (IBM, Armonk, NY, USA).

RESULTS

Demographic, clinical and laboratory characteristics of the 60 patients enrolled in the study are summarized in **Table 1**.

Briefly, mean age at data collection was 49.9 years old (SD ± 10.9) (females: males = 71.7%: 28.3%). Forty-three patients (71.7%) had a confirmed diagnosis of thrombotic APS (arterial 58.1%; venous 56.3%), and 17 patients presented with thrombosis and inconsistent LA positivity [7/17 (41.2%)] and/or with low-medium titers [10/17(58.8%)]. In the latest, 10/17 patients with suspected APS were tested positive (titer > 30 UI) for aPS/PT, IgG and/or IgM.

TABLE 1 | Characteristics of the patients included in the study.

	APS patients (43; 72%)	Suspected APS (17; 28%)
ANAGRAPHIC		
Mean age (\pm S.D.) at data collection	45.7 (\pm 11.9)	51.9 (\pm 7.3)
Females	30 (69.8%)	11 (64.7%)
CLINICAL MANIFESTATIONS		
Arterial thrombosis	21 (48.8%)	5 (29.4%)
Venous thrombosis	26 (60.5%)	12 (70.6%)
aPL PROFILE AT DIAGNOSIS		
LA (positive, <i>n</i>)*	37 (86%)	11 (64.7%)
aCL (IgG/M)*	22 (51.2%)	7 (41.2%)
a β 2GPI (IgG/M)*	23(53.5%)	6 (35.3%)
ANTICOAGULANT THERAPY AT THE MOMENT OF TESTING		
VKA (warfarin)	18 (41.9%)	2 (11.8%)
LMWH	8 (18.6%)	2 (11.8%)
DOAC	13 (30.2%)	0
Anti-platelets therapy	17 (39.5%)	13 (76.5%)

SD, Standard Deviation; APS, Antiphospholipid Syndrome; aPL, Antiphospholipid Antibodies; LA, Lupus Anticoagulant; aCL, Anticardiolipin Antibodies; anti- β 2GPI, Anti- β 2Glycoprotein I antibodies; VKA, Vitamin K antagonists; LMWH, Low Molecular Weight Heparins; DOAC, Direct Anticoagulants. *When considering patients with suspected APS: defined as inconsistent LA positivity and/or low levels of ACA IgG/IgM or anti- β 2GPI IgG/IgM antibodies 10–30 GPL/MPL.

Overall, categorical agreement for LA among all the four centers, as expressed by Cohen's *kappa* coefficients, ranged from 0.41 to 0.60 (corresponding to moderate agreement). The correlation among quantitative results for aPS/PT IgG/IgM was strong (Spearman *rho* 0.84; when dichotomizing for positive vs. negative results, Cohen's *kappa* coefficients = 0.81–1.00).

Overall categorical agreement is resumed in **Figure 1**.

We observed 27 (45.0% of the total) cases (15/20, 75% patients on VKA) in which LA results were discordant (defined by lack of agreement) or inconclusive. Conversely, in those cases, we observed a good correlation for aPS/PT IgG/IgM testing (Cohen's *kappa* coefficients = 0.81–1.00, Spearman *rho* 0.86).

When considering previous LA testing, we observed a statistically significant higher agreement among centers of LA testing if LA testing was previously positive [LA previously positive testing vs. negative: full agreement among centers 74.5% vs. 30.7% (*chi Square* test *p* < 0.05)]. Interestingly, the level of agreement of aPS/PT IgG/IgM among centers was similar regardless of previous LA testing [LA previously positive vs. negative: full agreement among centers 85.1% vs. 92.3% (*chi Square* test *p* = 0.49)].

When stratifying patients according to the inclusion criteria, we observed that in patients with confirmed diagnosis of APS, LA, and aPS/PT (IgG/IgM) agreements were 24/43 (55.8%) and 40/43 (93.0%), respectively. Conversely, in patients with thrombosis not completely fulfilling the Sydney laboratory criteria, we found aPL testing agreement among the four centers as follows: LA 9/17 (52.9%) and aPS/PT IgG/IgM 11/17 (64.7%).


DISCUSSION

The diagnosis and consequent management as well as the classification of APS relies on the identification of persistent aPL positivity in patients with thrombosis and/or pregnancy morbidity (11). Among aPL tests, LA has been shown to be the strongest risk factor for thrombotic events (15) and LA testing should always be performed in parallel with aCL and a β 2GPI (3, 16–18) when a patients is investigated for APS.

However, despite significant progress in LA testing thanks to the updated guidelines of the ISTH (12, 13), LA testing still suffers from some shortcomings and remain much more labor intensive and complicated to perform compared to immunoassays.

In our study, when testing for LA in a blind fashion in four centers all undergoing regular external quality assessment (EQA) (14), we observed that up to 45% of LA positive samples were not unanimously identified. When limiting the analysis to patients with VKA, the observed level of agreement dropped to 55%.

Is it well-known that one of the major drawbacks of LA tests is their sensitivity to anticoagulant therapy (such as VKA, and DOAC), due to the coagulation based principle. Preferably, tests should be postponed until therapy is stopped; however, in the real world, requests during therapy still occur very frequently with potentially false-positive or false-negative results (13, 19). In addition, it might be logistical inconvenient for the patients to switch (or stop) anticoagulant therapy for LA testing purpose.



When a thrombotic event occurs in patients suspected for APS with inconsistent LA positivity and/or with low-medium aPL titers, clinical management can be challenging, as no consensus exists on the choice and, more critically, the duration of anticoagulation in this setting. In this study, when analyzing patients not completely fulfilling the criteria for APS, we observed a level of LA agreement of only 53%, supporting the need of further diagnostic tool to help physicians in the management of these patients.

Autoantibodies directed toward PS/PT complexes have been extensively studied for their diagnostic and prognostic utility in patients with suspected APS (9). Due to the observation that anti-prothrombin antibodies associate significantly with LA (20–24), several studies have sought to define the diagnostic relevance of

these antibodies in APS (9, 23, 25, 26). Recent evidence support that while aPS/PT are frequently found in patients with LA, their association with thrombosis seems to be independent of the presence of LA (27).

Among the so-called extra-criteria aPL tests, besides aPS/PT, anti β 2GPI-domain1 antibodies have been also proposed to potentially improve the diagnostic accuracy in patients with suspected APS (28, 29), especially when assessing the risk for both thrombosis and pregnancy morbidity. Other antibody specificities, such as anti-annexin A5 and anti-vimentin antibodies, might be considered for thrombotic risk assessment only in selected patients, particularly when other aPL tests are negative and in the presence of clinical signs and/or symptoms strongly suggestive for APS (26, 30).

In our cohort, aPS/PT testing showed an overall agreement of 83% (up to 90% in patients receiving VKA), providing an overall increase in test reproducibility of +28% when compared to LA, becoming even more evident (+65%) when analyzing patients on VKA. These observations have important implications. On the one hand, LA testing remains a cornerstone for APS diagnosis. On the other, ongoing efforts to reduce the LA testing interlaboratory/interassay variations remain important. Taking into account the methodological shortcomings of LA, aPS/PT might represent a reliable and reproducible test, even during VKA or when APS diagnosis is uncertain. Besides the diagnosis, these findings also might have significant implications for classification criteria and therefore for clinical trials of new treatments.

Besides, albeit investigating the impact of aPS/PT testing on the management of patients with suspected APS was out of the scope of this study, one might note that up to nearly 60% of the patients with suspected APS were found positive for aPS/PT. From a speculative point of view, this observation might support a role for aPS/PT testing when APS is suspected but currently classification criteria aPL are not fully informative/reliable.

Although our investigation suffers for some limitations (cross-sectional approach limiting the analysis of the longitudinal fluctuation in aPL positivity; limited sample size; no further analysis on the level of agreement for aCL and a β 2GPI), the strengths of this study relies on the blind approach of aPL testing, performed in four different centers all undergoing periodic EQA. Besides, in this investigation, we evaluated the robustness of aPS/PT ELISA testing in different clinical settings, including patients suspected for APS but tested negative/low-titers for aCL and a β 2GPI antibodies. In such cases, a further diagnostic tool for APS with reliable performances might be crucial to guide the diagnostic process and to avoid under/over treatment (31). Finally, testing for aPS/PT by a commercial kit was proven to be a reproducible and accurate test for the detection of aPS/PT, bringing the added advantage of shorter running times when compared to in-house assays (32).

In conclusion, despite the progress in the standardization of aPL testing, we observed up to 45% of overall discrepant results for LA, even higher in patients on VKA. Our findings showed that the persistence of significant discordance in the reliability of LA testing. The introduction of aPS/PT antibodies in the diagnostic process of APS might represent a further valuable diagnostic tool, especially when LA is not available or reliable. In addition, detection of aPS/PT antibodies provides another tool which can complement and support current testing with aCL and a β 2GPI assays, and further help guiding clinical management.

DATA AVAILABILITY

This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations for rare diseases in Piedmont Region, Northwest Italy with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki.

AUTHOR CONTRIBUTIONS

SS, MR, IC, ER, MM, and DR drafted the manuscript, figures, and tables and critically reviewed the manuscript. AS, RR, BM, PP, GM, EMu, SB, MF, AV, and EMe participated in laboratory testing and critically reviewed the manuscript.

ACKNOWLEDGMENTS

This study was performed under the support of the School of Specialization of Clinical Pathology, Department of Clinical and Biological Sciences, University of Turin, Italy. The study was presented in abstract form during the American College of Rheumatology.

REFERENCES

1. Devreese KMJ. Standardization of antiphospholipid antibody assays. Where do we stand? *Lupus*. (2012) 21:718–21. doi: 10.1177/0961203312439335
2. Willis R, Lakos G, Harris EN. Standardization of antiphospholipid antibody testing—historical perspectives and ongoing initiatives. *Semin Thromb Hemost*. (2014) 40:172–7. doi: 10.1055/s-0033-1364207
3. Devreese KMJ. Antiphospholipid antibody testing and standardization. *Int J Lab Hematol*. (2014) 36:352–63. doi: 10.1111/ijlh.12234
4. Galli M, Luciani D, Bertolini G, Barbui T, Mackie J, Donohoe S, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. *Blood*. (2003) 101:1827–32. doi: 10.1182/blood-2002-02-0441
5. Devreese KMJ, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL. Subcommittee on lupus anticoagulant/phospholipid/dependent antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. *J Thromb Haemost*. (2014) 12:792–5. doi: 10.1111/jth.12537
6. Seheult JN, Meyer MP, Bontempo FA, Chibisov I. The effects of indirect- and direct-acting anticoagulants on lupus anticoagulant assays. *Am J Clin Pathol*. (2017) 147:632–40. doi: 10.1093/ajcp/axq035
7. Antovic A, Norberg E-M, Berndtsson M, Rasmuson A, Malmström RE, Skeppholm M, et al. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting. *Thromb Haemost*. (2017) 117:1700–4. doi: 10.1160/TH17-03-0204
8. Sciascia S, Amigo M-C, Roccatello D, Khamashta M. Diagnosing antiphospholipid syndrome: “extra-criteria” manifestations and technical advances. *Nat Rev Rheumatol*. (2017) 13:548–60. doi: 10.1038/nrrheum.2017.124
9. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome: a systematic review. *Thromb Haemost*. (2013) 111: 354–64. doi: 10.1160/TH13-06-0509
10. Amengual O, Forastiero R, Sugiura-Ogasawara M, Otomo K, Oku K, Favas C, et al. Evaluation of phosphatidylserine-dependent antiprothrombin

- antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. *Lupus*. (2017) 26:266–76. doi: 10.1177/0961203316660203
11. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost*. (2006) 4:295–306. doi: 10.1111/j.1538-7836.2006.01753.x
 12. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. *Thromb Haemost*. (1995) 74:1185–90.
 13. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. *J Thromb Haemost*. (2009) 7:1737–40. doi: 10.1111/j.1538-7836.2009.03555.x
 14. Bertero M, Bazzan M, Carignola R, Montaruli B, Silvestro E, Sciascia S, et al. Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): demographic features, risk factors, clinical and laboratory profile. *Lupus*. (2012) 21:806–9. doi: 10.1177/0961203312446974
 15. Toschi V, Motta A, Castelli C, Gibelli S, Cimminiello C, Molaro GL, et al. Prevalence and clinical significance of antiphospholipid antibodies to noncardiolipin antigens in systemic lupus erythematosus. *Haemostasis*. (1993) 23:275–83.
 16. Gebhart J, Posch F, Koder S, Perkmann T, Quehenberger P, Zoghiani C, et al. Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). *Blood*. (2015) 125:3477–83. doi: 10.1182/blood-2014-11-611129
 17. Pengo V, Testa S, Martinelli I, Ghirarduzzi A, Legnani C, Gresele P, et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. *Thromb Res*. (2015) 135:46–9. doi: 10.1016/j.thromres.2014.10.013
 18. Clark CA, Davidovits J, Spitzer KA, Laskin CA. The lupus anticoagulant: results from 2257 patients attending a high-risk pregnancy clinic. *Blood*. (2013) 122:341–7. doi: 10.1182/blood-2013-02-485839
 19. Zini G, D'Onofrio G, Briggs C, Erber W, Jou JM, Lee SH, et al. ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. *Int J Lab Hematol*. (2012) 34:107–16. doi: 10.1111/j.1751-553X.2011.01380.x
 20. Fleck R, Rapaport S, Rao L. Anti-prothrombin antibodies and the lupus anticoagulant. *Blood*. (1988) 72:512–9.
 21. Bertolaccini M. Antibodies to prothrombin. *Lupus*. (2012) 21:729–31. doi: 10.1177/0961203312443299
 22. Matsuda J, Saitoh N, Gotoh M, Kawasugl K, Gohchi K, Tsukamoto M. Phosphatidyl serine-dependent antiprothrombin antibody is exclusive to patients with lupus anticoagulant. *Br J Rheumatol*. (1996) 35:589–91.
 23. Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. *Arthritis Rheum*. (2000) 43:1982–93. doi: 10.1002/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2
 24. Arvieux J, Darnie L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. *Thromb Haemost*. (1995) 74:1120–5.
 25. Sanfelippo M, Joshi A, Schwartz S, Meister J, Goldberg J. Antibodies to phosphatidylserine/prothrombin complex in suspected antiphospholipid syndrome in the absence of antibodies to cardiolipin or Beta-2-glycoprotein I. *Lupus*. (2013) 22:1349–52. doi: 10.1177/0961203313497120
 26. Sciascia S, Radin M, Bazzan M, Roccatello D. Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome. *Intern Emerg Med*. (2017) 12:1–7. doi: 10.1007/s11739-016-1596-2
 27. Bertolaccini ML, Sciascia S, Murru V, Garcia-Fernandez C, Sanna G, Khamashta MA. Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS/PT) in patients with and without lupus anticoagulant. *Thromb Haemost*. (2013) 109:207–13. doi: 10.1160/TH12-07-0527
 28. Radin M, Cecchi I, Roccatello D, Meroni PL, Sciascia S. Prevalence and thrombotic risk assessment of Anti- β Glycoprotein I Domain I antibodies: a systematic review. *Semin Thromb Hemost*. (2017) 44:466–74. doi: 10.1055/s-0037-1603936
 29. Meroni PL. Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools. *Lupus*. (2016) 25:905–10. doi: 10.1177/0961203316641772
 30. Radin M, Cecchi I, Pérez-Sánchez C. Antiphospholipid antibodies negativization: time for testing for non-criteria aPL? *Lupus*. (2017) 26: doi: 10.1177/0961203317711014
 31. Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, Sanna G, Ateka-Barrutia O, Khamashta MA. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called “seronegative APS”). *Ann Rheum Dis*. (2012) 71:242–4. doi: 10.1136/annrheumdis-2011-200614
 32. Sciascia S, Sanna G, Murru V, Khamashta MA, Bertolaccini ML. Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients. *Thromb Res*. (2014) 133:451–4. doi: 10.1016/j.thromres.2013.12.001

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Sciascia, Radin, Cecchi, Rubini, Scotta, Rolla, Montaruli, Pergolini, Mengozzi, Muccini, Baldovino, Ferro, Vaccarino, Mahler, Menegatti and Roccatello. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.